Aldeyra Therapeutics to Announce Phase 3 Dry Eye Trial Results via Conference Call and Webcast

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) has announced an upcoming webcast and conference call scheduled for Thursday, August 8, 2024, at 9:00 a.m. (ET). The purpose of this event is to present the top-line results from their Phase 3 clinical trial focused on treating dry eye disease using the drug reproxalap. Interested parties can join the call using the provided domestic and international dial-in numbers, or access the live audio webcast through the "Investors & Media" section of Aldeyra's official website. The webcast will be available for replay on the website for 90 days following the live event.

Aldeyra Therapeutics is a biotechnology company dedicated to developing innovative treatments for immune-mediated and metabolic diseases. The company aims to create pharmaceuticals that modulate protein systems, rather than directly targeting single proteins, in an effort to optimize multiple biological pathways simultaneously and reduce toxicity. Aldeyra's product pipeline includes various RASP (reactive aldehyde species) modulators like ADX-629, ADX-248, ADX-743, and ADX-631, which are being explored for their potential in treating systemic and retinal immune-mediated and metabolic conditions.

Among Aldeyra's advanced product candidates are reproxalap, a RASP modulator intended for the treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a new formulation of intravitreal methotrexate designed to treat retinitis pigmentosa. The company's innovative approach seeks to address significant unmet medical needs by offering new therapeutic solutions for complex diseases.